Ponesimod

Sphingosine 1-phosphate Receptor Modulator — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Ponesimod is an onp drug in the Sphingosine 1-phosphate Receptor Modulator class catalogued in DrugCentral. It was first approved by the FDA in 2021. Its mechanism of action is classified as Sphingosine 1-Phosphate Receptor Modulators. DrugCentral lists 4 molecular targets, including S1PR1, S1PR5 and S1PR3. Recorded indications include Relapsing forms of multiple sclerosis.

• Approval status: onp (first approved 2021 by the FDA).
• Drug class: Sphingosine 1-phosphate Receptor Modulator.
• Mechanism of action: Sphingosine 1-Phosphate Receptor Modulators.
• Molecular targets: S1PR1, S1PR5, S1PR3 and S1PR4 (4 listed in DrugCentral).
• Indications: Relapsing forms of multiple sclerosis.
• ATC code: L04AE04 (Sphingosine-1-phosphate (S1P) receptor modulators).
• Molecular formula: C23H25ClN2O4S; molecular weight 460.97 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Relapsing forms of multiple sclerosis

Contraindications (9)

• Cerebrovascular accident
• Complete atrioventricular block
• Decompensated cardiac failure
• Heart failure
• Mobitz type II atrioventricular block
• Myocardial infarction
• Sick sinus syndrome
• Transient ischemic attack
• Unstable angina

Mechanism & targets

• Mechanism of action (MoA): Sphingosine 1-Phosphate Receptor Modulators
• Established pharmacologic class: Sphingosine 1-phosphate Receptor Modulator

Molecular targets (4)

Target	Gene	Action	Activity
Sphingosine 1-phosphate receptor 1	S1PR1	agonist	EC50 8.13
Sphingosine 1-phosphate receptor 5	S1PR5	agonist	EC50 7.23
Sphingosine 1-phosphate receptor 3	S1PR3	agonist	EC50 6.94
Sphingosine 1-phosphate receptor 4	S1PR4	agonist	EC50 5.96

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2021-05-19	EMA	—	Janssen-Cilag International N.V.
2021-03-18	FDA	—	JANSSEN PHARMACEUTICALS Inc

ATC classification

ATC code	Therapeutic hierarchy
L04AE04	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Sphingosine-1-phosphate (S1P) receptor modulators

Chemical structure

• Molecular formula: C₂₃H₂₅ClN₂O₄S
• Molecular weight: 460.97 g/mol
• CAS number: 854107-55-4
• InChIKey: LPAUOXUZGSBGDU-ULCCENQXSA-N
• PubChem CID: 11363176

CCCN=C1N(C(=O)/C(=C/C2=CC(=C(C=C2)OC[C@@H](CO)O)Cl)/S1)C3=CC=CC=C3C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ponesimod used for?

DrugCentral lists the following indications for Ponesimod: Relapsing forms of multiple sclerosis.

How does Ponesimod work?

Ponesimod is classified as Sphingosine 1-Phosphate Receptor Modulators; its molecular targets in DrugCentral include S1PR1 (agonist), S1PR5 (agonist), S1PR3 (agonist) and S1PR4 (agonist).

When was Ponesimod first approved?

Ponesimod was first approved by the FDA in 2021.

What drug class does Ponesimod belong to?

Ponesimod is in the Sphingosine 1-phosphate Receptor Modulator class.

What is the chemical formula of Ponesimod?

Ponesimod has the molecular formula C23H25ClN2O4S and a molecular weight of 460.97 g/mol.

Sources

• DrugCentral drug card 5446 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1096146 — compound record and bioactivity
• PubChem CID 11363176 — chemical identifiers
• DrugBank DB12016 — drug record
• FDA UNII 5G7AKV2MKP — substance identity
• DailyMed: FDA labels for Ponesimod — current prescribing information (label search)
• UniProt P21453 (S1PR1) — target protein
• UniProt Q9H228 (S1PR5) — target protein
• UniProt Q99500 (S1PR3) — target protein
• UniProt O95977 (S1PR4) — target protein

How this page is built: methodology · editorial policy & corrections.